AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie New Product or Indication Approvals (approvals) by Year
AbbVie New Product or Indication Approvals (approvals): 6 in FY2025, down 33.3% from a year earlier.
Latest, FY2025
6
Period ended Dec 31, 2025
Change on a year earlier
-33.3%
9 in FY2024
History
5 years
Since FY2021
Sources
2
Documents cited below
Where the FY2025 figure comes from
“Patients 13.8 9 6 10.8 7 5 6 4 7.8 Our People 2023 2024 2025 2023 2024 2025 2023 2024 2025 and Culture”
Source: AbbVie 2025 ESG Action Report ↗
Reported in AbbVie ESG Action Reports.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | New Product or Indication Approvals (approvals) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6 | -33.3% | AbbVie 2025 ESG Action Report ↗ |
| FY2024 | Dec 31, 2024 | 9 | +28.6% | AbbVie 2025 ESG Action Report ↗ |
| FY2023 | Dec 31, 2023 | 7 | -30.0% | AbbVie 2025 ESG Action Report ↗ |
| FY2022 | Dec 31, 2022 | 10 | 0.0% | AbbVie 2023 ESG Action Report ↗ |
| FY2021 | Dec 31, 2021 | 10 | – | AbbVie 2023 ESG Action Report ↗ |
Cite this data
StockData. (2026). AbbVie New Product or Indication Approvals (approvals), annual FY2021–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/rd-new-approvals
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.